Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) subsidiary Apitoria Pharma received two observations from the US Food and Drug Administration following the inspection of its facility.
The regulator inspected Unit V, an API manufacturing facility in the Sanga Reddy District of Telangana, India, from Dec. 9 to Dec. 17.
The pharmaceutical company said the observations were procedural and would be responded to within the stipulated time, according to a Tuesday filing to the stock exchanges.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.